Bexarotene
Brand names: Targretin
Bexarotene is a retinoid (rexinoid) used in the treatment of skin manifestations of advanced cutaneous T-cell lymphoma in patients refractory to at least one prior systemic therapy.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It selectively binds and activates retinoid X receptors, modulating gene transcription to influence cellular differentiation and apoptosis of malignant lymphocytes.
Prescribing in practice
- It commonly causes marked hyperlipidaemia and central hypothyroidism, which require baseline and ongoing monitoring and management.
- It is a specialist oral retinoid used only under supervision of clinicians experienced in cutaneous T-cell lymphoma.
- It is teratogenic and strictly contraindicated in pregnancy; concurrent vitamin A supplements and photosensitivity also warrant caution.
Monitoring
Monitor fasting lipids, thyroid function, full blood count and liver function before and regularly during treatment.
Counselling the patient
- Pregnancy must be avoided; use reliable contraception during and for a period after treatment.
- Avoid additional vitamin A supplements and limit sun exposure.
- Attend regular blood tests to check cholesterol and thyroid function.
Evidence & guidelines
Its activity in cutaneous T-cell lymphoma is supported by registration studies and reflected in its licensed indication and the SPC.
Reference: NICE TA177; BAD CTCL; ESMO; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Myeloid Leukaemia Presentation · BSH; NICE — NG146
- Tumour Lysis Syndrome · Cairo-Bishop; BSH; NICE — Best Practice
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023